GWM
SKYE icon

Gilpin Wealth Management’s Skye Bioscience SKYE Stock Holding History

Gilpin Wealth Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3 Buy
+1
New +$6 ﹤0.01% 1064

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Gilpin Wealth Management's SKYE Position: Q2 2026 in Review

Gilpin Wealth Management opened a new position in Skye Bioscience (SKYE) in Q2 2026: 1 share worth $3. The stake represents ﹤0.01% of the portfolio and ranks #1064 among its holdings.

33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Gilpin Wealth Management held 1 share of Skye Bioscience worth $3 as of Q2 2026.
  • Skye Bioscience was a new Gilpin Wealth Management position in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q2 2026, its #1064 holding.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.